TIDMVAL
RNS Number : 1439J
ValiRx PLC
14 August 2023
ValiRx PLC
("ValiRx" or the "Company")
Collaborative Services Agreement
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health,
announces that the CompanyÕs wholly owned subsidiary, Inaphaea
BioLabs Limited ("Inaphaea"), has entered into a collaborative
services agreement with Agility Life Sciences Limited ("Agility")
("Collaborative Services Agreement").
The Collaborative Services Agreement recognises the synergy
between Inaphaea's growing capabilities as a translational contract
research organisation (tCRO(R)) and Agility's capabilities for
formulation development and optimisation, pre-formulation studies
and analysis.
Under the agreement, service users of Inaphaea will be able to
benefit from Agility's capabilities in a single service contract
with Inaphaea and similarly, service users of Agility will be able
to access Inaphaea's capabilities through their service contract
with Agility. This will enable a coherent, single point of contact
for service users to formulate and test their drug candidates.
Dr Suzy Dilly, CEO at ValiRx explains "We have appreciated the
skills and creativity displayed by Agility during the two projects
we have run with them, so we're delighted to be able to offer these
capabilities to our service users, as well as to continue using
these capabilities for our in-house programmes.
"In a comparative manner to our collaborative services agreement
with Physiomics announced in April 2023, this new arrangement with
Agility further expands the Inaphaea service capability. This
agreement is very much reciprocal, and we expect to be able to
offer our services to Agility customers just as much as offering
their services to ours."
Professor Claire Thompson, CEO at Agility commented "We are
really excited about entering into this Collaborative Service
Agreement with Inaphaea. This will enable our clients to take the
next steps in their development programmes by testing their
prototype formulations in the Inaphaea cell based studies. We
believe this will be beneficial to both companies as well as to our
clients, creating a more comprehensive scientific environment, and
accelerating development timelines."
The Directors of the Company take responsibility for this
announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
Inaphaea BioLabs Limited www.inaphaea.com
Dr Andrew Carnegie, Head of Strategic Andrew.Carnegie@inaphaea.com
Commercial Development
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton Ð Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
------------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
------------------------------
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397
8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
------------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
------------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and womenÕs health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRxÕs portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
About Agility Life Sciences
Agility Life Sciences is an award-winning CDMO, accelerating
your milestones and futureproofing your products. Agility turns
badly behaved molecules into smart formulations which give them the
best chance of success in preclinical studies, and enable them to
be accelerated to clinic.
Their core expertise is in developing formulations for small
molecules and peptides for various routes of administration
including oral, ocular, IV, intranasal and topical.
The ÒFast Futureproof FormulationsÓ approach always starts with
an end in mind, developing products which enable molecules to be
accelerated from discovery to clinic. Developing and manufacturing
formulations to meet the needs of their clients includes:
Yen Overcoming solubility and permeability issues.
Yen Immediate, controlled and sustained release.
Yen Formulations and analytical methods suitable for preclinical
safety and efficacy studies, including GLP tox studies.
Yen Clinical and commercial prototypes.
Yen Reverse engineering of existing products.
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRNKNBPPBKDOFD
(END) Dow Jones Newswires
August 14, 2023 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Valirx (LSE:VAL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024